| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
BridgeBio Pharma (NASDAQ:BBIO) is set to give its latest quarterly earnings report on Wednesday, 2025-10-29. Here's what investors need to know before the announcement.
Analysts estimate that BridgeBio Pharma will report an earnings per share (EPS) of $-0.82.
The announcement from BridgeBio Pharma is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
Last quarter the company missed EPS by $0.27, which was followed by a 8.94% drop in the share price the next day.
Here's a look at BridgeBio Pharma's past performance and the resulting price change:
| Quarter | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.68 | -1.00 | -1.09 | -0.98 |
| EPS Actual | -0.95 | -0.88 | -1.40 | -0.86 |
| Price Change % | -9.00 | 5.00 | 0.00 | 1.00 |
Shares of BridgeBio Pharma were trading at $63.56 as of October 27. Over the last 52-week period, shares are up 163.51%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.
To track all earnings releases for BridgeBio Pharma visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: BBIO
